To improve the clinical efficacy of cancer vaccines in patients with metastatic disease, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome Tregs and allow the breakdown of the immunosuppressive tumor microenvironment.
Cancer Immunology and Immunotherapy / Edition 1
Adoptive Cellular Therapy. LAG3 in Cancer Immunotherapy. Immunologically Active Biomaterials for Cancer Therapy. Prognostic Significance and Disease Control. Klebanoff, Christopher A.
Kalos M. Karolina; Britten, Cedrik M. Edited by W. John W. Morrow, Nadeem A. Sheikh, Clint S. Schmidt, D. Jolanda M. Whiteside TL. Nakaya, Dmitri A. Kazmin, Jason Z. Kuprash, Svetlana V. Khlgatian, Ekaterina P. Koroleva, Alexey Y. Sazykin, Dmitry N. Penkov, Pavel V. Springer New York 95 The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study.
Lisa H. Gavilondoa, F. Bequet-Romeroa, J.
Valenzuelaa, Y. Selman-Houseinc, A.
- Cancer Immunology and Immunotherapy (Current Topics in Microbiology and Immunology, Vol. 344)?
- Sustainable Agriculture (Sustainanble Agriculture Book 1)?
- Article tools.
- School of Biomedical Sciences.
Garabitob, O. Lindsey Chudley, Katy J. Cazaly, Nicole Bidmon, Cedrik M. Britten, Sjoerd H. Stynenbosch, Steffen Walter, Marij J. Welters, Christian H.
Sanchez, Thomas N. Foureau, Asim Amin, Richard L. White, William Anderson, Chase P. Jones, Terry Sarantou, Iain H. McKillop, Jonathan C. Welters, Christian Ottensmeier, Sjoerd H. Beatty, Andrew R.
Table of contents
Haas, Marcela V. Maus, Drew A. Torigian, Michael C. Levine, Steven M. Albelda, Michael Kalos, and Carl H. Ottenhoff , Simone A. Roelandts, Heleen H.
Van Acker, Steven D. Heynderickx, Barbara M. Stein, Marc Peeters, Carl G. Figdor, Viggo F. Van Tendeloo, I. Jolanda de Vries, Gosse J. Adema, Zwi N. Berneman, Evelien L.dyfodotapiny.tk
Dr James Cronin
Rao, Nikola C. Teslovich, Michael B. Jackson, Suhas G. Kallapur, Alan H. Jobe andClaire A. Clifton, Holbrook E. Kohrt, George E. Rothman, Jeffrey R. Currier, Heather L. Janetzki S, Rabin R. CIR Immunomonitoring in glioma immunotherapy: current status and future perspectives Jonathan B. DiDomenico, Daniel E. Oyon, Andrew T.
Spotlight on Research
Martin, Scott D. Brown, Darin A. Wick, Julie S. Nielsen, David R. Holt, Brad H. Boer, Corine Prins, Krista E. Ottenhoff, and Simone A. Aguillon, Amy E. Harry, James A. Hutchinson, John D. Martinez-Caceres, Catharien M. Donald M. Ottenhoff Simone A. Plant, Anne L. Lill Peter A. T-cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assays. Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. Hoos, Axel; Eggermont, Alexander M.
MIATA | MIATA cited
Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Moodie, Z. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Mander, A. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Britten, C. A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols.
Related Cancer Immunology and Immunotherapy: 344 (Current Topics in Microbiology and Immunology)
Copyright 2019 - All Right Reserved